

August 26, 2019

### Announcement of Online Publication of RBM-007 Mediated Therapy for AMD and Presentation at EURETINA International Congress

TOKYO, August 26, 2019 – RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TSE-Mothers: 4591, President and CEO: Yoshikazu Nakamura, Ph.D., “RIBOMIC”) today announced the progress report on RBM-007 that is published online today and will be presented in an upcoming international congress.

As announced on June 17, 2019, RIBOMIC has successfully completed the phase 1/2a clinical trial of RBM-007 (SUSHI Study) in US for the treatment of wet age-related macular degeneration (AMD). The manuscript describing the mechanism of action of RBM-007 for AMD treatment is published online in *Molecular Therapy Nucleic Acids*. These results together with the positive top-line clinical data of the SUSHI study will be presented in the EURETINA 2019 International Congress to be held during September 5–8 in Paris (<http://www.euretina.org/paris2019/> ).

Manuscript title: Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease

([https://www.cell.com/molecular-therapy-family/nucleic-acids/pdfExtended/S2162-2531\(19\)30208-2](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdfExtended/S2162-2531(19)30208-2) )

Contacts for inquiries or additional information:

RIBOMIC Inc.

Corporate Planning Department

[ir.inquiry@ribomic.com](mailto:ir.inquiry@ribomic.com)